|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Recurrent Diffuse Pontine Gliomas | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Glioma | |||||
| Recurrence | |||||
| 3 | More general conditions related to this trial | ||||
| Disease Attributes | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Neoplasms, Nerve Tissue | |||||
| Neoplasms, Neuroepithelial | |||||
| Neuroectodermal Tumors | |||||
| Pathologic Processes | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Antibodies | |||||
| Antibodies, Monoclonal | |||||
| 5 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| YM BioSciences | |||||